Skip to main content

Published locations for Pembrolizumab, nivolumab linked to 3% rate of neurologic events

Primary tabs

  • View
  • Get Stamp Tags
  • Published Locations

Breadcrumb

  1. Home
  3. Pembrolizumab, nivolumab linked to 3% rate of neurologic events

User login

  • Reset your password
  • /content/pembrolizumab-nivolumab-linked-3-rate-neurologic-events
  • /familypracticenews/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /hematologynews/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /internalmedicinenews/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /oncologypractice/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /hematology-oncology/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /internalmedicine/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /neurology/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic-events
  • /familymedicine/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate-neurologic
  • /clinicalneurologynews/article/146091/immuno-oncology/pembrolizumab-nivolumab-linked-3-rate